#### ARRAY BIOPHARMA INC

Form 4 July 25, 2013

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB** Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

**OMB APPROVAL** 

if no longer subject to Section 16. Form 4 or Form 5

Check this box

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading MOORE JOHN R Issuer Symbol ARRAY BIOPHARMA INC (Check all applicable) [ARRY] (Last) (First) (Middle) 3. Date of Earliest Transaction Director 10% Owner X\_ Officer (give title \_ Other (specify (Month/Day/Year) below) 3200 WALNUT STREET 07/23/2013 VP, General Counsel (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) \_X\_ Form filed by One Reporting Person Form filed by More than One Reporting BOULDER, CO 80301 Person

| (City)                               | (State) (Z                              | Zip) Table  | e I - Non-Do                           | erivative S  | Securi           | ties Acq   | uired, Disposed o  | of, or Beneficial  | ly Owned  |
|--------------------------------------|---|---|--|--|------------------|------------|--|--|---|
| 1.Title of<br>Security<br>(Instr. 3) | 2. Transaction Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 3.<br>Transactio<br>Code<br>(Instr. 8) | 4. Securities Acquired action(A) or Disposed of (D) 8) (Instr. 3, 4 and 5) |                  |            | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following | 6. Ownership<br>Form: Direct<br>(D) or<br>Indirect (I)<br>(Instr. 4) | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
| Common                               |   |   | Code V                                 | Amount   | (A)<br>or<br>(D) | Price      | Reported<br>Transaction(s)<br>(Instr. 3 and 4)                   |  |   |
| Common<br>Stock                      | 07/23/2013                              |   | M <u>(1)</u>                           | 5,000  | A                | \$<br>2.74 | 16,886   | D  |   |
| Common<br>Stock                      | 07/23/2013                              |   | S(1)                                   | -,   | D                |            | 11,886   | D  |   |
| Common<br>Stock                      | 07/25/2013                              |   | M                                      | 4,759  | A                | \$<br>3.75 | 16,645   | D  |   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control

### Edgar Filing: ARRAY BIOPHARMA INC - Form 4

#### number.

Sec (In

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transactic<br>Code<br>(Instr. 8) | Transaction Derivative Code Securities |                     | cisable and<br>vate<br>Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |  | 8 II S ( |
|---|---|--------------------------------------|---|--|--|---------------------|------------------------------|---|--|----------|
|   |   |                                      |   | Code V                                 | (A) (D)                                | Date<br>Exercisable | Expiration<br>Date           | Title   | Amount<br>or<br>Number<br>of<br>Shares |          |
| Stock<br>Option<br>(Right to<br>Buy)                | \$ 2.74   | 07/23/2013                           |   | M                                      | 5,000                                  | (2)                 | 03/31/2020                   | Common<br>Stock   | 5,000                                  |          |
| Stock<br>Option<br>(Right to<br>Buy)                | \$ 3.75   | 07/25/2013                           |   | M                                      | 4,759                                  | (3)                 | 08/01/2013                   | Common<br>Stock   | 4,759                                  |          |

### **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

MOORE JOHN R 3200 WALNUT STREET

BOULDER, CO 80301

VP, General Counsel

Signatures

John R. Moore 07/25/2013

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2012.
- (2) The option vests in four equal annual installments beginning March 4, 2011.
- (3) The option vested in four equal annual installments beginning July 1, 2004.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2